Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 130-144

  Langer, Corey J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarker; Epidermal growth factor receptor (EGFR); Epidermal growth factor receptor (EGFR) mutation; Histology; Kirsten rat sarcoma viral oncogene homolog (KRAS); Molecular marker; Non small cell lung cancer (NSCLC)

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BMS 690514; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SORAFENIB; TAXANE DERIVATIVE; TIVANTINIB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ACNE; ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLEEDING DISORDER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 GENE; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OUTCOME ASSESSMENT; PARONYCHIA; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; TREATMENT DURATION; TREATMENT PLANNING; TREND STUDY; TUMOR GENE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861990751     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.09.004     Document Type: Review

References (112)

1. American Cancer Society Cancer facts & figures, 2010 2010, American Cancer Society, Atlanta, GA.
2. American Cancer Society. Detailed guide: lung cancer - non-small cell. What is non-small cell lung cancer? [accessed 08.07.10]. http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/lung-cancer--non-small-cell--non-small-cell-lung-cancer.
3. Garassino M.C., Borgonovo K., Rossi A., et al. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009, 29:2691-2701.
4. Azzoli C.G., Baker S., Temin S., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
5. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
6. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
7. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
8. Scagliotti G.V., Park K., Patil S., et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 2009, 45:2298-2303.
9. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
10. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
11. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
12. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
13. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118:257-262.
14. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
15. Rossi G., Pelosi G., Graziano P., Barbareschi M., Papotti M. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009, 17:206-218.
16. Downey P., Cummins R., Moran M., Gulmann C. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008, 116:526-529.
17. Jorda M., Gomez-Fernandez C., Garcia M., et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer Cytopathol 2009, 117:46-50.
18. Sibilia M., Kroismayr R., Lichtenberger B.M., Natarajan A., Hecking M., Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007, 75:770-787.
19. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
20. Hirsch F.R., Varella-Garcia M., Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009, 28(Suppl. 1):S32-S37.
21. Meert A.P., Martin B., Delmotte P., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002, 20:975-981.
22. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
23. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
24. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
25. Douillard J.Y., Shepherd F.A., Hirsh V., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2009, 28:744-752.
26. Khambata-Ford S., Harbison C.T., Hart L.L., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:918-927.
27. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
28. Perrone F. Cetuximab in NSCLC: another trial needed. Lancet Oncol 2011, 12:3-4.
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.3.2011. [accessed 21.05.11]. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
30. Pirker R., Paz Ares L., Eberhardt W.E.E., et al. Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung. Abstract associated with oral presentation at: the 14th Biennial world conference on lung cancer 2011, [abstract O01.06].
31. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
32. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
33. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
34. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
35. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
36. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
37. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
38. Zhu C.Q., da Cunha S.G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
39. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
40. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011.
41. Yang C-H., Fukuoka M., Mok T.S., et al. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) V carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (iPASS). Ann Oncol 2010, 21:viii1-viii2. [abstract LBA2].
42. Lee J.S., Park K., Kim S.W., et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009, 4:S283-S284. [abstract PRS.4].
43. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
44. Inoue A., Kobayashi K., Maemondo M., et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J Clin Oncol 2011, 29. [abstract 7519].
45. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
46. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011.
47. ® vs Chemotherapy) study: interim results of a phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutation. Abstract associated with oral presentation at: the 14th Biennial world conference on lung cancer 2011, [abstract O10.01].
48. Genentech Inc. FDA approves Tarceva as a maintenance therapy for advanced non-small cell lung cancer. [accessed 21.04.10]. http://www.gene.com/gene/news/press-releases/display.do%3Fmethod=detail%26id=12727.
49. Roche. Roche announces filing of Tarceva in EU as first-line maintenance therapy in advanced non-small cell lung cancer; 2009, March 19. [accessed 12.05.10]. http://www.roche.com/investors/ir_update/inv-update-2009-03-19.htm.
50. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
51. Turke A.B., Zejnullahu K., Wu Y.L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
52. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
53. Janjigian Y.Y., Groen H.J., Horn L., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29. [abstract 7525].
54. Eberhard D.A., Giaccone G., Johnson B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-994.
55. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
56. Cappuzzo F., Ligorio C., Janne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007, 25:2248-2255.
57. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23:6838-6845.
58. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
59. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
60. Hirsch F.R., Dziadziuszko R., Varella-Garcia L., et al. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naïve advanced NSCLC: correlation of biomarker status and clinical benefit. J Clin Oncol 2009, 27:8026.
61. Crino L., Cappuzzo F., Zatloukal P., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26:4253-4260.
62. Herbst R.S., Kelly K., Chansky K., et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group Study S0342. J Clin Oncol 2010, 28:4747-4754.
63. Khambata-Ford S., Harbison C., Woytowitz D., et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009, 27:8021.
64. Mack P.C., Holland W.S., Redman M., et al. KRAS mutation analysis in cetuximab treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 2009, 27:8002.
65. O'Byrne K.J., Gatzemeier U., Bondarenko I., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011.
66. Vincent M.D. Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 2009, 16:9-21.
67. Li D., Ambrogio L., Shimamura T., et al. BIBW2992 an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
68. Miller V.A., Hirsh V., Cadranel J., et al. Subgroup analysis of LUX-Lung 1: a randomized phase III trial of afatinib (BIBW 2992)+best supportive care (BSC) versus placebo+BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib. J Thorac Oncol 2010, 5. [abstract LBPL3].
69. Yang C., Shih J., Su W., et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). Ann Oncol 2010, 21:viii123. [abstract 367PD].
70. De Greve J., Decoster L., De Mey J., et al. Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2/neu. Presented at: the 2nd European lung cancer conference 2010.
71. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804 an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
72. Gonzales A.J., Hook K.E., Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008, 7:1880-1889.
73. Janne P.A., Boss D.S., Camidge D.R., et al. Phase I dose-escalation study of the Pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011, 17:1131-1139.
74. Janne P.A., Schellens J.H., Engelman J.A., et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 2008, 26:8027.
75. Janne P.A., Reckamp K., Koczywas M., et al. A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. J Thorac Oncol 2009, 4:S293-S294. [abstract A3.1].
76. Campbell A., Reckamp K.L., Camidge D.R., et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 2010, 28:7596.
77. Park K., Heo D.S., Cho B.C., et al. PF299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy and erlotinib or gefitnib: a phase I/II study. Oral presentation at: the 46th annual meeting of the American society of clinical oncology 2010.
78. Boyer M.J., Blackhall F.H., Park K., et al. Efficacy and safety of PF299804 versus erlotinib: a global, randomized phase 2 trial in patients with advanced non-small cell lung cancer after failure of chemotherapy. Oral presentation at: the 46th annual meeting of the American society of clinical oncology 2010.
79. Boyer M., Blackhall F.H., Barrios C.H., et al. Overall survival (OS) results of a randomized phase 2 trial of PF299804 versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. J Thorac Oncol 2011, 6.
80. Mok T., Spigel D.R., Park K., et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:7537.
81. Loriot Y., Mordant P., Dorvault N., et al. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 2010, 103:347-353.
82. Chow L.Q., Laurie S.A., Belani C.P., et al. Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. J Clin Oncol 2010, 28:2547. [meeting abstracts].
83. Bahleda R., Soria J.C., Harbison C.T., et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 2009, 27:431s. [abstract 8098].
84. Shaw A.T., Costa D.B., Iafrate A.J., et al. Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations. J Thorac Oncol 2009, 4:S305. [abstract A6.4].
85. Wong D.W., Leung E.L., So K.K., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
86. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
87. Camidge D.R., Bang Y., Iafrate A.J., et al. Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21:viii123. [abstract 366PD].
88. Camidge D.R., Bang Y., Kwak E.L., et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29.
89. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
90. Crino L., Kim D., Riely G.J., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011, 29. [abstract 7514].
91. Food and Drug Administration FDA News Release. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. [accessed 29.08.11]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.
92. Laux I., Goldman J., Just R., et al. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 2009, 27:3549.
93. Schiller J.H., Akerley W.L., Brugger W., et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:LBA7502.
94. Rosell R., Lord R.V., Taron M., Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227.
95. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
96. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
97. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766.
98. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
99. Rosell R., Felip E., Taron M., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10:4215s-4219s.
100. Boukovinas I., Papadaki C., Mendez P., et al. RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008, 3:e3695.
101. Cobo M., Massuti B., Morán T., et al. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. J Clin Oncol 2008, 26:7533.
102. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
103. Massuti B., Cobo M., Sanchez J.M., et al. The pharmacogenomic approach in adjuvant setting of NSCLC: postoperative chemotherapy customized according BRCA1 levels: docetaxel single agent arm compared with platinum doublets; SCAT pilot trial results. J Thorac Oncol 2009, 4:S299. [abstract A4.4].
104. Li Z., Zhou S., Zhang L., Ren S., Zhou C. RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy. J Thorac Oncol 2009, 4:S915-S916.
105. Kim E.S., Herbst R.S., Lee J.J., et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. Presented at: the 101st annual meeting of the American association for cancer research 2010.
106. Herbst R.S., Blumenschein G.R., Kim E.S., et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol 2010, 28:7609. [meeting abstracts].
107. Heymach J.V., Saintigny P., Kim E.S., et al. Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination). Presented at: the 102nd annual meeting of the American association for cancer research 2011, [abstract LB-88].
108. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27:4232-4235.
109. Weiss J., Sos M.L., Seidel D., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2:62ra93.
110. Hirsch F.R., Varella-Garcia M., Dziadziuszko R., et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008, 14:6317-6323.
111. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
112. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081-8092.